Fig. 2: IMBlaze370 control cohort attrition. | Communications Medicine

Fig. 2: IMBlaze370 control cohort attrition.

From: Hybrid-control arm construction using historical trial data for an early-phase, randomized controlled trial in metastatic colorectal cancer

Fig. 2

The external-control cohort was built with the MORPHEUS trial eligibility criteria applied in the IMBlaze370 control cohort. 3 L third-line, 5FU fluorouracil, BRAF B-Raf proto-oncogene, serine/threonine kinase, EGFR epidermal growth factor receptor, MSI-H microsatellite instability–high.

Back to article page